Home / Clinical Trial / ANZadapt

Current Clinical Trials

ANZadapt

 Prostate — In Follow-up

Cancer is a disease that changes over time. When cancer changes, a treatment that worked before might start to become less effective. Hormone tablets are approved in Australia to treat advanced prostate cancer, however, even if these drugs are helpful their effectiveness usually diminishes over time. The ANZadapt trial is testing a new idea to try to slow down the changes in cancer by giving treatment for just long enough to control the cancer, and then pausing the treatment if the cancer is controlled. If the cancer starts to grow again, the treatment is started again to try to control the cancer again. This idea is called ‘adaptive therapy’ as the treatment is adapted for each person. Adaptive therapy may slow how cancer changes and keep treatment useful for as long as possible when a treatment can control a cancer, but can't cure the cancer. The ANZadapt aims to find out if this pause/restart strategy is better than taking hormone tablets every day continuously.

If you think this trial might be right for you, please ask your doctor.

TRIAL TITLE

Phase II randomised controlled trial of patient-specific adaptive versus continuous Abiraterone or eNZalutamide in metastatic castration-resistant prostate cancer

CONSUMER TITLE

Study testing whether adaptive (pause–restart) hormone treatment compared to continuous treatment improves outcomes for people with advanced prostate cancer. Participants are randomly assigned to different treatment groups.

CANCER TYPE

Prostate

TRIAL STATUS

In Follow-up

PROTOCOL NUMBER

ANZUP 2101

CO-ORDINATING CENTRE

STUDY CHAIR

Craig Gedye

PATIENT POPULATION

Patients with asymptomatic or minimally symptomatic metastatic CRPC in whom treatment with AA or ENZ is indicated.

RECRUITMENT TARGET

84 patients in Australia and New Zealand

ACKNOWLEDGEMENT

The ANZadapt Trial is an investigator-initiated trial sponsored and led by ANZUP. This trial has received funding from a philanthropic grant awarded by the Anticancer Fund (ACF) in Belgium. This trial is a collaboration between ANZUP, the Hunter Medical Research Institute (HMRI) Clinical Trials Unit and the Leiden University Medical Center (LUMC)

DETAILED INFORMATION

LATEST PUBLICATION